The best of times, the worst of times for psychiatric disease

被引：34

作者：

Karayiorgou, Maria ^{[1
]}

Flint, Jonathan ^{[2
]}

Gogos, Joseph A. ^{[3
,4
]}

Malenka, Robert C. ^{[5
]}

机构：

[1] Columbia Univ, Med Ctr, Dept Psychiat, New York, NY 10027 USA

[2] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England

[3] Columbia Univ, Med Ctr, Dept Neurosci, New York, NY USA

[4] Columbia Univ, Med Ctr, Dept Physiol & Cellular Biophys, New York, NY USA

[5] Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA

来源：

NATURE NEUROSCIENCE | 2012年 / 15卷 / 06期

基金：

英国惠康基金;

关键词：

D O I：

10.1038/nn.3115

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

As long-awaited advances in psychiatric genetics begin to materialize in force, promising to steer us safely to the best of times in psychiatric disease research, many pharmaceutical companies pull away from the challenge of drug development, threatening to bring us to the worst of times for the field. There is a real danger of missed opportunities and a sense of urgency for defining a clear path forward.

引用

页码：811 / 812

页数：2